Mineralys Therapeutics (MLYS) Preferred Shares Issued (2022)
Quarterly results put Preferred Shares Issued at -$105.7 million for Q4 2022, changed N/A from a year ago — trailing twelve months through Sep 2023 was -$105.7 million (changed N/A YoY), and the annual figure for FY2022 was $12.0 million, changed.
Mineralys Therapeutics has reported Preferred Shares Issued over the past 1 years, most recently at -$105.7 million for Q4 2022.
- Preferred Shares Issued reached -$105.7 million in Q4 2022 per MLYS's latest filing, down from $105.7 million in the prior quarter.
- Across five years, Preferred Shares Issued topped out at $105.7 million in Q3 2022 and bottomed at -$105.7 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -105.67 Mn |
| Dec 31, 2022 | -105.67 Mn |
| Sep 30, 2022 | 105.67 Mn |
| Sep 30, 2022 | 105.67 Mn |
| Jun 30, 2022 | -6,000.00 |
| Jun 30, 2022 | -6,000.00 |
| Mar 31, 2022 | 12.00 Mn |
| Mar 31, 2022 | 12.00 Mn |